Nicotinic acetylcholine receptor alpha-4 beta-2 subtype (α4β2 nAChR) (α4β2 nAChR)

The alpha-4 beta-2 (α4β2) nicotinic acetylcholine receptor is a pentameric ligand-gated ion channel and the most prevalent nicotinic receptor subtype in the human central nervous system (UniProt, 2023). It plays a critical role in mediating the effects of endogenous acetylcholine and exogenous nicotine, particularly within the mesolimbic dopamine system, which governs reward and reinforcement (PubMed, 2021). This receptor is a primary therapeutic target for smoking cessation, as partial agonists like varenicline can alleviate withdrawal symptoms while blunting the rewarding effects of nicotine (StatPearls, 2023). Beyond addiction, α4β2 receptors are implicated in cognitive processes and neurodegenerative conditions such as Alzheimer's and Parkinson's diseases, where their expression is often significantly reduced (NIH, 2022). Mutations in the genes encoding this receptor, CHRNA4 and CHRNB2, are also linked to specific forms of epilepsy, such as autosomal dominant nocturnal frontal lobe epilepsy (NCBI, 2020). Pharmacological modulation of this receptor is also being explored for the treatment of depression and attention deficit hyperactivity disorder due to its influence on neurotransmitter release (PubMed, 2022). Consequently, the receptor remains a focal point for developing cognitive enhancers and treatments for various neuropsychiatric disorders.

Other names

Neuronal nicotinic acetylcholine receptor alpha-4 beta-2CHRNA4-CHRNB2 receptorAlpha-4 beta-2 nicotinic receptor

Partial agonism, full agonism, antagonism, and positive allosteric modulation.